Antibacterials: Vive la difference!


novel classes of antibacterials have tended to focus on genomic targets that share little or no similarity to human proteins in order to attain bacterial selectivity. However, this approach has had limited success so far, perhaps in part because it limits the ability to apply the extensive drug discovery experience with compound classes commonly screened… (More)
DOI: 10.1038/nrd2832


Cite this paper

@article{Flight2009AntibacterialsVL, title={Antibacterials: Vive la difference!}, author={Monica Hoyos Flight}, journal={Nature Reviews Drug Discovery}, year={2009}, volume={8}, pages={193-193} }